NSE filing, NSE: DRREDDY. Summary written from the filing by ALFA Finder's alert engine.
Dr. Reddy's Laboratories Ltd: key numbers
- Share price
- ₹1,368.30
- Market cap
- ₹1,14,209 Cr
- Revenue (annual)
- ₹33,700 Cr
- Net profit (annual)
- ₹4,196 Cr
- P/E (TTM)
- 40.8×Sector 41.3×
- Promoter holding
- 26.63%-0.01% QoQ
- FII holding
- 20.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Reddy's Laboratories Ltd
All →Dr. Reddy's Laboratories Employee Stock Options
Dr. Reddy's allotted 5,91,270 equity shares to employees on exercise of stock options under its ADR ESOP Scheme 2007. Exercise prices ranged from Re.1 to Rs.1,060.20 per share.
Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Dr. Reddy's Laboratories Earnings Call Transcript: Key Takeaways
Revenue declined 1.5% YoY as lower Revlimid sales in North America offset strong double-digit growth in base business and emerging markets.
- Call
- Guides 25% growth
Dr. Reddy's Laboratories Management Change
Dr Reddy's appointed Akhil Ravi as Head API and Services and Senior Management Personnel, effective 13 November 2026. Ravi is the son-in-law of co-chairman G V Prasad.
Dr. Reddy's Laboratories Investor Presentation: Key Takeaways
Q2FY27 revenue ₹8,671 Cr (-1.5% YoY), EBITDA ₹1,783 Cr (20.6%), PAT ₹925 Cr (-36% YoY). Management stresses double-digit base-business growth excluding lenalidomide in North America.
Dr. Reddy's Laboratories Q2 FY27 Results: Net Profit ₹913.2 Cr, Down 31.7% YoY
Dr. Reddy's Laboratories Ltd reported revenue from operations of ₹8,698 Cr (-1.5% YoY) and net profit of ₹913.2 Cr (-31.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹913.2 Cr · -31.7% YoY
Other price movement clarification announcements
All →Aegis Logistics Price Movement Clarification
Aegis Logistics clarified to BSE that the unusual volume surge is purely market-driven with no undisclosed information. The company confirmed compliance with Reg 30 LODR.
Marsons Price Movement Clarification
Marsons Ltd. replied to an exchange price-movement query stating no undisclosed information exists. The company affirmed compliance with LODR and no future disclosure is pending.
Yaap Digital Price Movement Clarification
Yaap Digital told NSE no undisclosed event explains its recent share price movement. The Company confirmed all disclosures are timely and the movement is market-driven.
Quality RO Industries Price Movement Clarification
Quality RO Industries clarified BSE's surveillance query on share price movement, stating it was purely market-driven with no undisclosed material information.
Mahanagar Telephone Nigam Price Movement Clarification
MTNL responded to an NSE surveillance query on a volume spurt, stating no undisclosed material information exists. The share price movement is attributed to market conditions alone.
CIAN Agro Industries & Infrastructure Price Movement Clarification
CIAN Agro clarified to BSE that its recent significant share price movement is driven by market conditions. Management says it has no knowledge of the reasons and will keep complying with Regulation 30.